OPKO Health, Inc. Gain (Loss) on Repurchase of Debt Instrument
OPKO Health, Inc. (OPK) reported Gain (Loss) on Repurchase of Debt Instrument of -$8.69 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnRepurchaseOfDebtInstrument · last filed 2014-03-03
- OPKO Health, Inc. gain (loss) on repurchase of debt instrument for the quarter ending 2013-12-31 was $0.00.
- OPKO Health, Inc. gain (loss) on repurchase of debt instrument for the quarter ending 2012-12-31 was $0.00.
- OPKO Health, Inc. gain (loss) on repurchase of debt instrument for fiscal 2013 was -$8.69M.
- OPKO Health, Inc. gain (loss) on repurchase of debt instrument for fiscal 2012 was $0.00.
- OPKO Health, Inc. gain (loss) on repurchase of debt instrument for fiscal 2011 was $0.00.
| Period end | Gain (Loss) on Repurchase of Debt Instrument 3 month | Gain (Loss) on Repurchase of Debt Instrument 9 month | Gain (Loss) on Repurchase of Debt Instrument 12 month |
|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$8.69M 10-K · filed 2014-03-03 | |
| 2013-09-30 | -$8.69M 10-Q · filed 2013-11-12 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $0.00 10-K · filed 2014-03-03 | |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-12 | ||
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |